Articles tagged with Cancer Treatments
Dr. Aditya Bardia has been elected to the American Society for Clinical Investigation for his outstanding contributions to research and patient care in breast cancer treatment. He is advancing precision medicine therapies through antibody-drug conjugates and liquid biopsy technologies.
Researchers discovered a powerful molecule called miR-181d that weaks tumors and helps the immune system fight back against glioblastoma. The study found that tumors in 'exceptional responders' contain higher levels of miR-181d, which blocks cancer cells' ability to repair DNA damage.
Researchers found that tumor genetics alone did not explain which patients responded to combination therapy, but rather the tumor's immune environment. Patients with active networks of cancer-killing T cells were more likely to benefit from treatment, while those with dense clusters of plasma cells were less likely.
Chemokines regulate immune cell infiltration and local immunity in tumors, and targeting their receptor axis has emerged as a promising therapeutic target in cancer immunotherapy. Chemokine-modulating strategies combining with other immunotherapies have demonstrated considerable synergistic potential.
The Alliance for Clinical Trials in Oncology has several active trials specifically designed to help people with head and neck cancers. Trials include testing high-dose prophylactic gabapentin to prevent opioid use during treatment, as well as immunotherapy with nivolumab and cabozantinib for mucosal melanoma and nasopharyngeal carcino...
A specific protein, PKC-eta, has been identified as a central driver of aggressive breast cancer cell migration and metastasis. Reducing PKC-eta activity significantly slows tumor growth and reduces metastatic spread in laboratory and animal models.
A new study led by Dartmouth Cancer Center identifies key barriers to timely head and neck cancer treatment in rural areas, including transportation and caregiver challenges. The research highlights the importance of dedicated staff, strong community ties, and peer support in navigating the complexity of cancer care.
A new study reveals that cancer cells may begin escaping therapy much earlier, triggered by a stress response that drives them into a temporary drug-tolerant state. Researchers identified an early molecular trigger: NF-κB, which acts as a regulator of cellular stress and survival.
A large DRUP trial reveals that existing targeted cancer therapies can deliver profound and durable benefits, even in heavily pretreated or rare cancers. About one-third of patients responded to treatment or had stable disease for at least four months.
Researchers identified a CRISPR variant that distinguishes tumor DNA from healthy DNA and selectively cuts the former. This method relies on methyl groups attached to DNA, which are altered in cancer cells.
Researchers from UT MD Anderson Cancer Center present studies on single-cell technologies, integrative computational approaches, and experimental therapeutics, highlighting innovations in mRNA vaccines and spatial multi-omics techniques. The studies aim to improve immunotherapy responses and detect treatment-resistant glioma cells.
A University of Calgary-led study found that multiple myeloma tumour cells adapt in multiple ways to become resistant to treatment, highlighting the need for personalized cancer therapy. The research aims to develop next-generation treatments designed to anticipate and overcome these changes.
Ovarian cancer cells induce adipose tissue dysfunction and ADSC senescence, creating favorable conditions for tumor metastasis. Targeting senescent ADSCs with dasatinib plus quercetin or resveratrol achieves remarkable efficacy in delaying tumor progression and reducing metastases.
A clinical trial aims to evaluate whether laser therapy reduces vaginal dryness caused by breast cancer treatment. The study, REVITALIZE, plans to enroll approximately 250 women with a history of breast cancer who experience moderate to severe vaginal dryness.
This study reveals that lymphoma cells exhibit organotropism based on their germ-layer origin, with different mutations affecting migration patterns and survival. The research provides insights into the molecular basis of tumor invasion and metastasis, offering a new perspective for personalized cancer treatment.
A comprehensive review highlights FAK's driving role in tumor progression, immune evasion, and resistance to modern cancer therapies. Emerging strategies targeting FAK's enzymatic and scaffold functions hold promise for overcoming resistance mechanisms.
A new study reveals that two key BET proteins, BRD2 and BRD4, perform distinct roles in gene activation. Blocking both simultaneously disrupts the process, producing unpredictable effects. Targeted therapies may be more effective if they distinguish between these roles.
A randomized trial found that duloxetine does not prevent painful neuropathy caused by oxaliplatin-based chemotherapy in patients with stage II or III colorectal cancer. The study suggests that duloxetine should only be used for managing existing neuropathy, not prevention.
The European Association of Nuclear Medicine (EANM) has joined the EMUC26 congress to promote nuclear medicine expertise in urological cancers. The event will bring together healthcare professionals from various disciplines to discuss current practices and emerging innovations.
Researchers developed an AI model to predict Barrett's esophagus recurrence after endoscopic eradication therapy. The tool shows high accuracy in identifying patients at risk and detecting when recurrence is likely to occur.
The study found that immune checkpoint inhibitors significantly improved key clinical outcomes, including disease-free survival and distant metastasis-free survival. However, no clear improvement in overall survival was observed across studies, highlighting the need for careful patient selection and monitoring.
Weill Cornell Medicine researchers will explore novel combination therapies to address the gap in treatment options for patients with advanced urinary tract cancers. The study aims to understand how inherited genetic alterations and tumor-acquired mutations cooperate to disrupt DNA repair and drive cancers of the urinary tract.
A study from Japan has revealed a gradual increase in tAML rates, especially after breast cancer treatment. The study analyzed data from the Osaka Cancer Registry and found that the annual incidence of tAML increased from 0.13 to 0.36 per 100,000 population between 1990 and 2020.
The Alliance for Clinical Trials in Oncology is enrolling adolescent and young adult cancer patients in various trials, including genetic services and treatment studies. These trials aim to address longstanding gaps in care and improve outcomes for AYAs with cancer.
Therapy-related myeloid neoplasms (t-MN) pose a significant threat to female cancer survivors, with limited treatment options and high mortality rates. New therapies and diagnostic approaches, such as CAR-T and hypomethylating agents, offer hope for improved treatment outcomes and prevention.
The NCCN 2026 Annual Conference emphasized the need for holistic care for adolescents and young adults with cancer, highlighting unique challenges and the importance of supportive services. The conference also addressed global cancer care realities and future strategies, emphasizing the need for collaboration and investment to address ...
A Rutgers study found that a protein called PHGDH can predict drug response in cancer patients and improves survival rates when combined with immunotherapy. High levels of PHGDH are associated with better responses to anti-PD-1 therapy, suggesting it could be a potential biomarker.
A phase 1/2 clinical study found that pralsetinib improved durable responses with manageable safety profiles in patients with advanced or metastatic RET fusion-positive non-small cell lung cancer. The overall response rate was 78% and median duration of response was longer in patients with the CCDC6-RET fusion gene.
Researchers have uncovered how BAP1 functions at the molecular level and present a novel therapeutic strategy to slow cancer progression. BAP1's role in DNA repair pathways and its potential as a biomarker for personalized treatment are also explored.
Researchers used machine learning methods to identify safe time windows for outpatient stem cell therapy in multiple myeloma patients. The study found that this approach can predict adverse events and enable more precise risk assessment.
A study found that tumor DNA in patients' blood can predict whether breast cancer will return, especially after neoadjuvant treatment. Patients with detectable DNA at the end of treatment were 3.5 times more likely to relapse during follow-up.
A comprehensive review of BNCT suggests it can precisely target and destroy cancer cells while sparing healthy tissue. The therapy has shown promising results in extending overall survival and improving quality of life for patients with various types of malignant tumors.
A new study found that the common blood pressure medication telmisartan can significantly enhance the cancer-killing activity of olaparib, potentially expanding its use to many more patients. Telmisartan made tumors more vulnerable to PARP inhibitors, even when they lacked specific DNA repair defects.
A new analysis shows elinzanetant effectively relieves moderate-to-severe vasomotor symptoms (VMS) associated with endocrine therapy, regardless of the type of hormone treatment. The drug reduces VMS frequency and severity by blocking a protein that triggers these symptoms.
A pilot study found that axillary radiotherapy may be as effective as surgery in killing cancer cells while reducing the risk of painful swelling. The trial compared radiotherapy to axillary lymph node dissection and found similar cancer outcomes, but lower rates of lymphoedema after radiotherapy.
A new study shows that polyurethane-coated breast implants are associated with lower rates of capsular contracture and the need for corrective surgery after radiotherapy. Women who received these implants had a significantly lower risk of developing scarring and needing further surgery compared to those who received standard implants.
A recent study found that breast cancer recurrence remains low even after ten years when patients receive tailored radiotherapy. The research involved 848 patients who underwent chemotherapy and surgery, and showed that radiotherapy can be reduced or eliminated in low-risk patients, leading to a significant decrease in side effects.
The European project CGI-Clinics brings AI-powered Cancer Genome Interpreter (CGI) closer to clinical applications, enabling reliable and scalable tumour genome interpretation in precision oncology. The platform leverages machine learning to transform complex genomic data into actionable insights.
A new study from Aarhus University reveals the thymus, a small organ previously believed to cease functioning early in adult life, plays a lifelong role in the risk of cancer and cardiovascular disease. The healthier the thymus, patients respond better to immunotherapy treatment.
A new clinical trial will investigate whether adding the oral medication vorasidenib to standard chemotherapy improves progression-free survival for people with newly-diagnosed, grade 3 IDH-mutant astrocytoma. The study aims to recruit 400 individuals with this type of brain cancer and evaluate the safety and side-effect profile of the...
A recent study found that women have a 21% lower risk of death compared to men, but a 12% higher risk of severe side effects from cancer treatment. The research, conducted in partnership with international collaborators, analyzed data from over 20,000 cancer patients and identified sex-based differences in survival and treatment toxicity.
Researchers have identified and resolved molecular bottlenecks to produce doxorubicin, a vital chemotherapy agent, resulting in a 180% increase in production. This breakthrough enables cost-effective manufacturing of essential antibiotics and anti-cancer agents, promising a cleaner and more reliable supply of life-saving medicines.
Researchers explored using CDK4/6 inhibitors to treat PDAC by targeting RB1, which is often inactivated by oncogenic KRAS. This approach showed promise in inducing cellular senescence, but further combination therapy is needed for therapeutic benefit.
The NRG-LU005 trial found that immunotherapy atezolizumab did not improve survival for patients with limited-stage small cell lung cancer when added to chemoradiation. Twice-daily radiation therapy, however, was associated with improved survival in this population.
Recent advances in photonic nanomaterials and healthcare devices have led to the development of wearable and implantable medical devices. These devices utilize light for precise manipulation of cells and tissues, offering new possibilities for early disease detection, light-based therapies, and personalized precision medicine.
A phase 3 clinical trial by Mass General Brigham reveals romiplostim's ability to prevent chemotherapy-induced thrombocytopenia, allowing full-dose chemotherapy delivery. The medication boosts bone marrow's resistance to chemotherapy, reducing the risk of life-threatening bleeding and improving cancer treatment outcomes.
The Sylvester Cancer Tip Sheet for March 2026 highlights the importance of genetic testing for cancer risk assessment. Researchers have made significant progress in developing new treatments, including mRNA-based immunotherapy for colorectal and pancreatic cancers. Additionally, the Dolphins Cancer Challenge has surpassed $100 million ...
Researchers discovered yaku'amide B induces CD9 degradation, a cancer stem cell-related protein, in addition to inhibiting ATP synthase, leading to cellular energy depletion and cancer cell suppression. This natural compound has potential as a new therapeutic approach for cancer treatment.
The Alliance trial explores the combination of zanubrutinib and sonrotoclax for CLL treatment, aiming to send cancer into remission and allow patients to stop treatment earlier. The study has the potential to be life-changing for patients and their families, reducing the burden of ongoing therapy and improving quality of life.
Researchers discover a potential chemotherapy agent that causes cancer cells to release signals similar to those released by infected cells, triggering an immune response. This finding could lead to a new approach in cancer treatment, using lower doses of chemotherapy drugs to recruit the immune system as an ally.
Blocking two key 'don't eat me signals' in cancer cells heightens the immune response and sensitizes tumors to immunotherapy in glioblastoma models. Researchers found that simultaneously blocking CD47 and CD24 improved immunotherapy response, allowing macrophages to better recognize and attack cancer cells.
Researchers at Weill Cornell Medicine have identified the FOXJ1 gene as a key player in chemotherapy resistance in prostate cancer. The study found that increased FOXJ1 levels in tumors can make cancer cells less responsive to taxane chemotherapy, leading to poorer outcomes for patients.
Ochsner MD Anderson Cancer Center will be the first in the southern US to offer biology-guided radiotherapy (BgRT), a breakthrough treatment that uses cancer biology to guide radiotherapy delivery. This new therapy aims to provide more focused and accurate treatment with fewer side effects for patients.
The Alliance for Clinical Trials in Oncology is spotlighting new trials for colorectal cancer in March, focusing on early detection methods and treatments for treatment delays and loss of appetite. The trials aim to improve patient outcomes, with several enrolling patients with newly diagnosed colon or rectal cancer.
Singapore's breast cancer incidence is rising, but mortality rates are falling, mirroring global trends. The country's strong healthcare system and high-screening participation have contributed to improved survival rates.
A new study demonstrates that blocking a signaling protein called FAK helps mobilize an anti-tumor immune response, allowing tumor-fighting cells to approach tumors and shift the behavior of other immune cells to work against them. This approach achieved the best effects on immune cell recruitment, tumor size reduction, and survival ti...
A new study from Memorial Sloan Kettering Cancer Center reveals that analyzing a patient's genomic profile can predict breast cancer resistance to CDK4/6 inhibitors. The researchers found that inheriting a BRCA2 mutation and other genetic alterations increase the likelihood of resistance. This discovery provides a new strategy for pred...
The study discovered that restoring cellular vibration decreases cancer growth and severity in laryngeal cancer. Researchers exposed cancer cells to sound-wave vibration, leading to a decrease in a protein promoting cancer growth.
A study published in Science Advances reveals a mechanism to bind to intrinsically disordered proteins, providing a new approach for therapeutic design. The research, led by Dr. Xavier Salvatella, shows that these proteins adopt more organized conformations when clustering, allowing for selective binding by a drug.